Cargando…
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
Epithelial ovarian cancer (EOC) is the fifth most common cancer affecting the female population. At present, different targeted treatment approaches may improve currently employed therapies leading either to the delay of tumor recurrence or to disease stabilization. In this study we show that syndec...
Autores principales: | Orecchia, Paola, Balza, Enrica, Pietra, Gabriella, Conte, Romana, Bizzarri, Nicolò, Ferrero, Simone, Mingari, Maria Cristina, Carnemolla, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769537/ https://www.ncbi.nlm.nih.gov/pubmed/31443604 http://dx.doi.org/10.3390/cancers11091232 |
Ejemplares similares
-
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
por: Orecchia, Paola, et al.
Publicado: (2015) -
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
por: Mortara, Lorenzo, et al.
Publicado: (2018) -
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine
por: Mortara, Lorenzo, et al.
Publicado: (2013) -
Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010) -
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)